Poliothrysoside and its derivatives as novel insulin sensitizers potentially driving AMPK activation and inhibiting adipogenesis

European Journal of Medicinal Chemistry

Volumn 86, Issue , 2014, Pages 570-577

  Sashidhara, Koneni V ^a   Singh, Suriya P ^a   Varshney, Salil ^a   Beg, Muheeb ^a   Gaikwad, Anil N ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

3T3 L1 adipocytes; AMPK; Insulin resistance; Non insulin dependent type 2 diabetes; Poliothrysoside

Indexed keywords

2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 (1 ETHOXY 1 OXOPROPAN 2 YLOXY)BENZYL ALCOHOL; 2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 (2 ETHOXY 2 OXOETHOXY)BENZYL ALCOHOL; 2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 (2 OXO 2 PARA TOLYLETHOXY)BENZYL ALCOHOL; 2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 (2 OXO 2 PHENYLETHOXY)BENZYL ALCOHOL; 2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 (2 TERT BUTOXY 2 OXOETHOXY)BENZYL ALCOHOL; 2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 (2,5 DICHLOROBENZYLOXY)BENZYL ALCOHOL; 2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 (3 CHLOROBENZYLOXY)BENZYL ALCOHOL; 2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 (4 NITROBENZYLOXY)BENZYL ALCOHOL; 2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 BENZYLOXYBENZYL ALCOHOL; 2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 ETHOXYBENZYL ALCOHOL; 2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 METHOXYBENZYL ALCOHOL; 2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 [2 (4 CHLOROPHENYL) 2 OXOETHOXY]BENZYL ALCOHOL; 2 (6 BENZOYL BETA GLUCOPYRANOSYLOXY) 5 [2 (4 METHOXYPHENYL) 2 OXOETHOXY]BENZYL ALCOHOL; 2 (6 BENZOYL BETAGLUCOPYRANOSYLOXY) 5 [2 (4 METHOXYPHENYL) 2 OXOETHOXY]BENZYL ALCOHOL; 2 BETA GLUCOPYRANOSYLOXY 5 HYDROXYBENZYL ALCOHOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN SENSITIZING AGENT; METFORMIN; POLIOTHRYSOSIDE; POLIOTHRYSOSIDE PENTAACETATE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BENZOIC ACID DERIVATIVE; GLUCOSIDE;

ADIPOCYTE; ADIPOGENESIS; ANTIDIABETIC ACTIVITY; ARTICLE; FLACOURTIA INDICA; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; SALICACEAE; 3T3 CELL LINE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM; MOUSE; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BENZOATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GLUCOSIDES; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MICE; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907857483     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.09.015     Document Type: Article

References (33)

1. S.S. Albrecht, E.V. Kuklina, P. Bansil, D.J. Jamieson, M.K. Whiteman, A.P. Kourtis, S.F. Posner, W.M. Callaghan, Diabetes trends among delivery hospitalizations in the U.S., 1994-2004, Diabetes Care 33 (2010) 768-773.
2. R.H. Eckel, S.M. Grundy, P.Z. Zimmet, The metabolic syndrome, Lancet 365 (2005) 1415-1428.
3. C.V. Desouza, G.B. Bolli, V. Fonseca, Hypoglycemia, diabetes, and cardiovascular events, Diabetes Care 33 (2010) 1389-1394.
4. C.M. Clark Jr., D.A. Lee, Prevention and treatment of the complications of diabetes mellitus, N. Engl. J. Med. 332 (1995) 1210-1217.
5. T. Ogihara, H. Rakugi, H. Ikegami, H. Mikami, K. Masuo, Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives, Am. J. Hypertens. 8 (1995) 316-320.
6. D.E. Moller, New drug targets for type 2 diabetes and the metabolic syndrome, Nature 414 (2001) 821-827.
7. M. Adamczak, A. Wiecek, The adipose tissue as an endocrine organ, Semin. Nephrol. 33 (2013) 2-13.
8. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M.F. Hirshman, L.J. Goodyear, D.E. Moller, Role of AMP-activated protein kinase in mechanism of metformin action, J. Clin. Invest. 108 (2001) 1167-1174.
9. S.A. Hawley, A.E. Gadalla, G.S. Olsen, D.G. Hardie, The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism, Diabetes 51 (2002) 2420-2425.
10. J.M. Ye, N.B. Ruderman, E.W. Kraegen, AMP-activated protein kinase and malonyl-CoA: targets for treating insulin resistance? Drug. Disc. Today Ther. Strateg. 2 (2005) 157-163.
11. M.C. Towler, D.G. Hardie, AMP-activated protein kinase in metabolic control and insulin signaling, Circ. Res. 100 (2007) 328-341.
12. B.B. Zhang, G. Zhou, C. Li, AMPK: an emerging drug target for diabetes and the metabolic syndrome, Cell Metab. 9 (2009) 407-416.
13. L.G.D. Fryer, A. Parbu-Patel, D. Carling, The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways, J. Biol. Chem. 277 (2002) 25226-25232.
14. M.J. Fowler, Diabetes treatment, part 2: oral agents for glycemic management, Clin. Diabetes 25 (2007) 131-134.
15. S.E. Nissen, K. Wolski, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N. Engl. J. Med. 356 (2007) 2457-2471.
16. E. Rattanangkool, P. Kittikhunnatham, T. Damsud, S. Wacharasindhu, P. Phuwapraisirisan, Quercitylcinnamates, a new series of antidiabetic bioconjugates possessing alpha-glucosidase inhibition and antioxidant, Eur. J. Med. Chem. 66 (2013) 296-304.
17. S. Sirasanagandla, R.B. Kasetti, A.N. Shaik, R. Natava, V.P. Surtineni, S.R. Cirradur, A. Chippada, Antihyperglycemic and antihyperlipidemic activities of 2-(4-[(2-hydroxybenzyl) amino]-phenyl amino-methyl)-phenol in STZ induced diabetic rats, Eur. J. Med. Chem. 66 (2013) 400-406.
18. V.S. Patil, K.P. Nandre, S. Ghosh, V.J. Rao, B.A. Chopade, B. Sridhar, S.V. Bhosale, S.V. Bhosale, Synthesis, crystal structure and antidiabetic activity of substituted (E)-3-(benzo [d]thiazol-2-ylamino) phenylprop-2-en-1-one, Eur. J. Med. Chem. 59 (2013) 304-309.
19. C.J. Bailey, C. Day, Metformin: its botanical background, Pract. Diab. Int. 21 (2004) 15-17.
20. Y.S. Lee, W.S. Kim, K.H. Kim, M.J. Yoon, H.J. Cho, Y. Shen, J.M. Ye, C.H. Lee, W.K. Oh, C.T. Kim, C. Hohnen-Behrens, A. Gosby, E.W. Kraegen, D.E. James, J.B. Kim, Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states, Diabetes 55 (2006) 2256-2264.
21. T. Szkudelski, K. Szkudelska, Anti-diabetic effects of resveratrol, Ann. N. Y. Acad. Sci. 1215 (2011) 34-39.
22. B. Dasgupta, J. Milbrandt, Resveratrol stimulates AMP kinase activity in neurons, Proc. Natl. Acad. Sci. 104 (2007) 7217-7222.
23. E.J. Kim, D.H. Lee, H.J. Kim, S.J. Lee, J.O. Ban, M.C. Cho, H.S. Jeong, Y. Yang, J.T. Hong, Y. Yoon do, Thiacremonone, a sulfur compound isolated from garlic, attenuates lipid accumulation partially mediated via AMPK activation in 3T3- L1 adipocytes, J. Nutr. Biochem. 23 (2012) 1552-1558.
24. S.K. Kim, C.S. Kong, Anti-adipogenic effect of dioxinodehydroeckol via AMPK activation in 3T3-L1 adipocytes, Chem. Biol. Interact. 186 (2010) 24-29.
25. H.X. Wang, T.B. Ng, Natural products with hypoglycemic, hypotensive, hypocholesterolemic, antiatherosclerotic and antithrombotic activities, Life Sci. 65 (1999) 2663-2677.
26. V. Singh, M. Singh, S. Shukla, S. Singh, M.H. Mansoori, M.L. Kori, Antidiabetic effects of Flacourtia indica Merr in streptozotocin induced diabetic rats, Glob. J. Pharmacol. 5 (2011) 147-152.
27. M. Bourjot, P. Leyssen, C. Eydoux, J.-C. Guillemot, B. Canard, P. Rasoanaivo, F. Gueritte, M. Litaudon, Flacourtosides A-F, phenolic glycosides isolated from flacourtia ramontchi, J. Nat. Prod. 75 (2012) 752-758.
28. M. Manickam, M. Ramanathan, M.A.F. Jahromi, J.P.N. Chansouria, A.B. Ray, Antihyperglycemic activity of phenolics from Pterocarpus marsupium, J. Nat. Prod. 60 (1997) 609-610.
29. A. Muhammad, J.A. Guerrero-Analco, L.C. Martineau, L. Musallam, P. Madiraju, A. Nachar, A. Saleem, P.S. Haddad, J.T. Arnason, Antidiabetic compounds from Sarracenia purpurea used traditionally by the Eeyou Istchee Cree First Nation, J. Nat. Prod. 75 (2012) 1284-1288.
30. K.V. Sashidhara, S.P. Singh, S.V. Singh, R.K. Srivastava, K. Srivastava, J.K. Saxena, S.K. Puri, Isolation and identification of beta-hematin inhibitors from Flacourtia indica as promising antiplasmodial agents, Eur. J. Med. Chem. 60 (2013) 497-502.
31. M.J. Thomson, M.G. Williams, S.C. Frost, Development of insulin resistance in 3T3-L1 adipocytes, J. Biol. Chem. 272 (1997) 7759-7764.
32. K.L. Hoehn, C. Hohnen-Behrens, A. Cederberg, L.E. Wu, N. Turner, T. Yuasa, Y. Ebina, D.E. James, IRS1-independent defects define major nodes of insulin resistance, Cell Metab. 7 (2008) 421-433.
33. C.M. Taniguchi, B. Emanuelli, C.R. Kahn, Critical nodes in signalling pathways: insights into insulin action, Nat. Rev. Mol. Cell Biol. 7 (2006) 85-96.